vaccin
elicit
protect
broadli
neutral
antibodi
bnab
respons
monoclon
antibodi
therapi
critic
treatment
prevent
viral
infect
howev
isol
protect
neutral
antibodi
challeng
virus
notabl
high
antigen
divers
elicit
bnab
respons
cours
natur
infect
discuss
recent
work
employ
protein
engin
strategi
design
immunogen
elicit
bnab
engin
novel
bnab
highlight
use
ration
comput
combinatori
strategi
assess
potenti
approach
develop
new
vaccin
immunotherapeut
introduct
viral
vaccin
th
centuri
led
signific
decreas
viral
diseas
burden
worldwid
viral
vaccin
thought
work
induc
product
antibodi
block
infect
reduc
viral
load
therebi
provid
host
protect
blunt
infect
cellular
immun
effect
antibodi
particip
host
defens
sever
way
includ
opson
coat
virus
enhanc
uptak
phagocyt
cell
activ
complement
famili
protein
directli
destroy
pathogen
enhanc
phagocyt
uptak
focu
neutral
antibodi
bind
viru
prevent
infect
neutral
antibodi
protect
mani
virus
anim
human
therefor
much
interest
identif
character
potenti
use
immunotherapeut
agent
serv
templat
immunogen
design
neutral
antibodi
histor
identifi
immun
anim
viral
compon
bcell
repertoir
human
vaccine
survivor
recent
year
increas
amount
structur
inform
neutral
antibodi
mechan
activ
shift
focu
toward
structurebas
design
immunogen
design
elicit
antibodi
antibodi
neutral
antibodi
thought
abrog
viral
infect
three
major
mechan
figur
block
viru
attach
host
cell
ii
inhibit
viral
uncoat
conform
chang
viral
envelop
glycoprotein
need
cell
entri
iii
induc
format
noninfecti
viral
aggreg
enter
cell
case
envelop
virus
surround
lipid
bilay
primari
neutral
target
viru
envelop
glycoprotein
respons
mediat
membran
fusion
viral
host
cell
membran
critic
step
infect
cours
natur
infect
vaccin
neutral
antibodi
mani
virus
polio
mump
measl
elicit
human
anim
howev
induct
effect
neutral
antibodi
rare
occur
virus
notabl
high
antigen
divers
human
immunodefici
hepat
c
viru
influenza
viru
surprisingli
antigen
variat
reflect
divers
sequenc
viru
envelop
glycoprotein
among
strain
clade
thu
antibodi
bind
conserv
epitop
narrow
spectrum
activ
variou
strategi
employ
develop
vaccin
elicit
neutral
antibodi
high
divers
virus
vaccin
trial
use
adjuv
enhanc
qualiti
antibodi
respons
vaccin
nucleicacid
base
method
deliveri
antigen
administr
one
type
vaccin
boost
immunogen
attempt
howev
effect
vaccin
virus
remain
elus
major
hurdl
appear
immunodomin
antibodi
respons
direct
variabl
part
envelop
glycoprotein
therefor
neutral
antibodi
narrowli
strainspecif
effect
vaccin
abl
elicit
broadli
neutral
antibodi
bnab
engag
conserv
less
variabl
domain
therefor
protect
across
spectrum
genet
isol
likewis
immunotherapeut
virus
direct
conserv
viral
epitop
infect
pathway
review
highlight
recent
work
util
novel
protein
engin
strategi
develop
effect
vaccin
immunotherapeut
highli
variabl
virus
virus
bnab
respons
aris
cours
natur
infect
one
promis
strategi
gener
bnab
vaccint
revers
engin
structur
inform
glean
bind
bnab
rais
cours
natur
infect
use
guid
immunogen
design
theori
translat
antibodi
bind
inform
immunogen
design
display
specif
critic
epitop
allow
product
antibodi
similar
broad
neutral
capac
vivo
provid
immunolog
evolut
pathway
bnab
induc
vaccin
thought
modif
immunogen
reflect
specif
threedimension
antibodybind
site
requir
figur
sinc
goal
revers
engin
develop
peptid
protein
scaffold
mimic
natur
epitop
strategi
util
ration
combinatori
comput
method
discuss
sever
recent
exampl
method
use
develop
evalu
immunogen
lentiviru
enter
host
cell
fuse
lipid
bilay
host
cell
plasma
membran
fusion
facilit
viral
envelop
glycoprotein
env
consist
surfac
subunit
transmembran
subunit
infect
initi
bind
coreceptor
host
cell
trigger
largescal
conform
chang
eventu
lead
membran
fusion
antibodi
direct
env
potenti
neutral
gener
bnab
proven
extrem
challeng
like
hypervari
encod
env
gene
extens
glycosly
surfac
env
protein
structur
heterogen
associ
critic
function
trigger
molecul
membran
fusion
cours
chronic
infect
patient
develop
bnab
suggest
vaccin
approach
prevent
infect
possibl
number
bnab
target
epitop
region
membraneproxim
extern
region
mper
structur
bnab
bound
peptid
epitop
demonstr
segment
contain
welldefin
secondari
structur
bound
bnab
therefor
hypothes
immunogen
design
elicit
antibodi
bind
segment
conform
would
critic
success
vaccin
strategi
immunogen
base
loop
design
far
met
limit
success
antibodi
isol
via
hybridoma
method
subtyp
b
individu
found
bind
tip
loop
conform
chakraborti
et
al
design
synthes
peptid
immunogen
mimic
tip
region
insert
epitop
thioredoxin
small
stabl
e
coli
protein
use
newli
introduc
disulfid
bond
lock
epitop
desir
conform
construct
abl
gener
respons
upon
immun
guineapig
although
fairli
high
antibodi
concentr
elicit
immun
strategi
ugml
serum
serum
abl
effect
neutral
mani
primari
viral
isol
perhap
low
access
loop
mani
isol
mor
et
al
synthes
librari
peptid
vari
posit
disulfid
bond
within
peptid
group
found
contain
singl
disulfid
bond
regardless
posit
retain
flexibl
form
ideal
turn
howev
instal
second
disulfid
bond
led
signific
improv
peptid
rigid
mani
disulfid
bondcontain
peptid
exhibit
higher
affin
correspond
linear
peptid
constrain
peptid
link
segment
region
known
induc
helper
tcell
respons
shown
elicit
stronger
neutral
respons
rabbit
compar
analog
linear
peptid
construct
display
loop
studi
suggest
care
design
protein
mimic
natur
bnab
bind
site
potenti
elicit
neutral
respons
two
potent
bnab
known
target
bind
linear
epitop
mper
mper
highli
conserv
tryptophanrich
region
believ
play
crucial
role
membran
fusion
epitop
neighbor
one
anoth
appear
requir
bind
crucial
residu
within
respect
epitop
antibodi
shown
interact
virion
lipid
membran
addit
bind
suggest
structur
membraneanchor
mper
crucial
bind
mab
breadth
potenc
neutral
exhibit
antibodi
strategi
aim
elicit
respons
subject
mani
effort
develop
effect
antihiv
vaccin
isol
well
decad
ago
effort
mimic
epitop
design
immunogen
ongo
sinc
recent
sever
novel
bnab
isol
mper
one
exampl
mab
isol
hivinfect
donor
huang
et
al
one
potent
broadli
neutral
antihiv
antibodi
yet
identifi
shown
bind
mper
conform
similar
novel
bind
epitop
presenc
mperbind
antibodi
natur
infect
suggest
appropri
design
immunogen
would
elicit
similar
antibodi
ofek
et
al
use
comput
method
construct
epitop
scaffold
use
epitop
epitop
conform
flexibl
bound
antibodi
therefor
pose
particular
challeng
epitop
design
upon
bind
mper
epitop
adopt
kink
extend
structur
recognit
specif
structur
postul
requir
neutral
activ
ofek
et
al
therefor
strove
mimic
structur
comput
design
immunogen
group
first
search
protein
data
bank
pdb
acceptor
protein
could
use
scaffold
segment
contain
backbon
structur
similar
epitop
identifi
protein
redesign
use
rosettadesign
introduc
mutat
mper
epitop
side
chain
would
includ
scaffold
construct
use
vaccin
trial
use
mice
although
antibodi
similar
bind
mode
identifi
vaccin
trial
fail
produc
neutral
sera
howev
crystal
structur
result
antibodi
complex
hiv
mper
demonstr
segment
correspond
epitop
adopt
desir
kink
extend
structur
correia
et
al
perform
similar
studi
use
linear
epitop
appropri
scaffold
protein
identifi
pdb
optim
use
rosettadesign
result
epitop
construct
found
bind
higher
affin
case
higher
compar
mper
peptid
epitop
alon
epitopescaffold
use
immun
trial
rabbit
shown
induc
antibodi
nonneutr
display
high
structur
similar
discuss
known
requir
interact
virion
lipid
membran
bind
therefor
approach
may
requir
modif
incorpor
membranelik
compon
elicit
antibodi
nonetheless
studi
demonstr
appropri
engin
immunogen
contain
segment
mimic
conform
featur
linear
epitop
use
gener
structurespecif
antibodi
epitop
azoitei
et
al
develop
comput
experiment
methodolog
incorpor
backbon
conform
side
chain
function
motif
onto
appropri
protein
scaffold
exampl
protein
graft
involv
transplant
protein
side
chain
onto
acceptor
protein
scaffold
alreadi
contain
nativ
segment
backbon
conform
match
linear
epitop
bnabbound
conform
howev
approach
limit
acceptor
protein
segment
match
epitop
conform
epitop
region
must
identifi
work
azoitei
et
al
develop
method
incorpor
side
chain
backbon
epitop
scaffold
impos
desir
epitop
conform
protein
design
author
found
epitop
backbon
graft
result
scaffold
bound
higher
affin
correspond
sidechain
graft
construct
therefor
backbon
graft
may
prove
success
gener
bnab
side
chain
graft
although
immun
trial
yet
perform
construct
design
use
methodolog
bnab
target
linear
epitop
viral
glycoprotein
mani
known
bnab
target
epitop
consist
discontinu
protein
segment
therefor
neutral
requir
recognit
specif
threedimension
conform
viral
antigen
present
challeng
immunogen
design
must
accur
recapitul
threedimension
antibodi
bind
epitop
addit
challeng
mani
viral
glycoprotein
structur
heterogen
therefor
crucial
design
immunogen
mimic
structur
epitop
relev
antibodi
neutral
case
highlight
problem
face
effect
viral
immunogen
design
chen
et
al
use
model
bind
experi
explor
differ
potent
bnab
target
site
poorli
neutral
antibodi
also
target
site
found
even
slight
differ
bind
site
order
angstrom
suffici
result
differ
antibodi
neutral
capabl
exampl
antibodi
whose
angl
approach
site
differ
otat
variabl
region
bind
substanti
differ
conform
therefor
one
explan
failur
viral
immunogen
translat
effect
vaccin
thu
far
may
immunogen
design
suffici
precis
natur
interact
antibodi
elicit
recent
attempt
overcom
challeng
turn
advanc
comput
combinatori
protein
design
method
azoitei
et
al
use
combin
comput
experiment
approach
graft
nonlinear
discontin
epitop
acceptor
protein
scaffold
result
immunogen
observ
bind
tightli
bind
sitetarget
nonneutr
antibodi
wu
et
al
use
protein
engin
gener
variant
preserv
bind
site
elimin
antigen
region
substitut
surfac
expos
residu
includ
bind
site
simian
immunodefici
viru
homolog
nonhiv
residu
ident
resurfac
core
figur
design
intend
focu
interact
site
sinc
antibodi
interact
segment
would
bind
resurfac
segment
resurfac
core
use
bait
screen
use
broadli
neutral
serum
human
patient
potent
bnab
identifi
expect
variant
design
bind
bind
site
antibodi
identifi
hivinfect
individu
shown
broadli
neutral
across
hiv
genet
isol
interestingli
antibodi
deriv
germlin
segment
promis
observ
induct
similar
bnab
sinc
antibodi
origin
germlin
segment
estim
present
human
antibodi
repertoir
howev
predict
germlin
progenitor
antibodi
show
bind
wildtyp
therefor
unlik
could
elicit
antibodi
sinc
unabl
engag
appropri
unmut
progenitor
address
problem
jardin
et
al
recent
use
combin
computationallyguid
antigen
design
vitro
screen
engin
immunogen
bind
multipl
bnab
germlin
precursor
figur
jardin
et
al
first
built
homolog
model
germlin
precursor
bound
model
reveal
area
potenti
steric
clash
glycan
germlin
antibodi
figur
inset
group
gener
outer
domain
od
construct
clash
remov
rosetta
comput
protein
interfac
use
identifi
addit
mutat
site
predict
increas
affin
germlin
progenitor
librari
mutat
screen
use
yeast
display
outer
domain
variant
identifi
screen
subject
round
comput
design
librari
screen
well
select
retent
bind
final
result
iter
process
construct
term
shown
bind
nanomolar
affin
antibodi
lower
micromolar
affin
germlin
progenitor
fuse
selfassembl
viruslik
nanoparticl
shown
activ
germlin
matur
b
cell
construct
yet
evalu
vaccin
trial
rabbit
mice
macaqu
lack
germlin
segment
bear
homolog
nonetheless
may
promis
immunogen
candid
elicit
bnab
furthermor
concept
target
immunogen
engag
earli
fulli
matur
form
antibodi
along
immunolog
evolut
pathway
merit
evalu
influenza
rna
viru
caus
respiratori
tract
infect
mammal
bird
speci
influenza
envelop
viru
contain
two
coat
protein
hemagglutinin
ha
respons
host
cell
receptor
bind
membran
fusion
neuraminidas
na
cleav
sialic
acid
residu
releas
newli
bud
viral
particl
host
cell
case
env
high
degre
antigen
divers
toler
ha
na
thu
explain
influenza
abil
evad
host
immun
respons
caus
repeat
infect
singl
host
highli
infecti
pandem
influenza
outbreak
occur
approxim
everi
year
result
larg
chang
recombin
ha
andor
na
term
antigen
shift
highli
contagi
lethal
outbreak
caus
great
concern
worldwid
particular
influenza
resurg
led
concern
pandem
potenti
highlight
need
vaccin
effect
multipl
genet
isol
gile
ross
util
novel
comput
antigen
design
techniqu
term
cobra
comput
optim
broadli
reactiv
antigen
gener
synthet
ha
protein
capabl
elicit
broadli
neutral
antibodi
respons
avian
influenza
virus
divid
among
distinct
clade
geograph
divers
classifi
accord
phylogent
distanc
among
ha
gene
one
approach
address
vast
sequenc
divers
circul
isol
gener
consensusbas
viral
protein
use
immunogen
popul
sequenc
align
common
residu
posit
within
viral
protein
select
strategi
met
success
consensusbas
ha
immunogen
elicit
broad
antibodi
respons
mice
ferret
macaqu
howev
gile
ross
rais
concern
bia
inher
consensusbas
method
reli
avail
input
sequenc
therefor
subject
sampl
bia
author
point
major
ha
sequenc
human
isol
aris
clade
therefor
concern
sequenc
accur
reflect
true
divers
vial
sequenc
circul
avian
popul
cobra
method
use
overcom
concern
use
multipl
round
consensu
gener
cobra
method
perform
follow
uniqu
ha
sequenc
repres
clade
virus
group
phylogenet
subclad
divid
individu
outbreak
group
base
time
geograph
locat
isol
consensu
ha
sequenc
gener
outbreak
group
consensu
sequenc
gener
subclad
base
result
outbreak
group
subclad
consensu
sequenc
align
gener
final
consensu
sequenc
term
clade
cobra
ha
phylogenet
comparison
final
consensu
sequenc
human
isol
ha
sequenc
demonstr
clade
cobra
ha
retain
clade
sequenc
fall
specif
within
subclad
classif
inde
clade
cobra
ha
repres
uniqu
ha
sequenc
previous
isol
vlp
display
clade
cobra
ha
surfac
shown
bind
ha
receptor
sialic
acid
mice
ferret
cynomolgu
macaqu
vaccin
clade
cobra
ha
vlp
demonstr
protect
level
antiha
antibodi
seri
viral
isol
repres
subclad
clade
interestingli
clade
cobra
ha
vlp
found
elicit
highertit
antibodi
panel
ha
protein
mixtur
vlp
vaccin
express
repres
ha
molecul
clade
result
suggest
cobraderiv
sequenc
elicit
effici
antibodi
respons
immunogen
design
singl
genet
isol
altern
vaccin
strategi
immunogen
design
elicit
neutral
antibodi
respons
monoclon
antibodi
mab
administ
directli
therapeut
intervent
mab
use
clinic
treat
varieti
diseas
sinc
first
patient
treat
mab
unit
state
nonhodgkin
lymphoma
abil
mab
precis
target
specif
cell
protein
receptor
mab
therapi
cancer
therapeut
quickli
acceler
despit
clear
advantag
mab
offer
tradit
chemotherapeut
regim
term
specif
cell
target
earli
therapeut
trial
limit
immunogen
murin
antibodi
scaffold
upon
repeat
exposur
result
shorter
mab
halflif
lack
antibodi
effector
function
human
antimous
antibodi
hama
respons
caus
fever
chill
rash
nausea
headach
rare
anaphylaxi
limit
overcom
develop
humanmous
chimera
fulli
human
antibodi
current
mab
approv
fda
clinic
use
unit
state
twentyon
fulli
human
six
humanmurin
chimera
three
murin
one
antibodi
palivizumab
synagi
fulli
human
mab
approv
prophylaxi
respiratori
syncyti
viru
demonstr
mab
therapi
effect
viral
target
palivizumab
remain
therapi
significantli
reduc
rsv
hospit
rate
high
risk
infant
reduc
subsequ
morbiditymort
howev
worth
note
costeffect
palivizumab
question
antibodi
administ
monthli
inject
five
month
rsv
season
averag
seventeen
children
must
treat
manner
prevent
one
rsvrelat
hospit
admiss
fiftynin
must
treat
prevent
one
icu
admiss
palivizumab
cover
nation
health
servic
australia
uk
concern
costeffect
tradit
mab
viral
target
isol
immunizedinfect
anim
human
studi
antibodyantigen
complex
mainli
xray
crystallographi
allow
antibodi
engin
primarili
within
cdr
enhanc
potenc
natur
occur
antibodi
computeraid
analysi
allow
antibodi
engin
even
absenc
highresolut
structur
data
engin
base
structur
examin
comput
method
ration
mutat
introduc
mab
order
improv
affin
convey
desir
properti
crossreact
solubl
thu
facilit
identif
neutral
antibodi
therapeut
challeng
virus
highlight
recent
exampl
engin
antivir
mab
end
discuss
synthet
antibodi
engin
potenti
techniqu
appli
viral
therapeut
diskin
et
al
use
structur
inform
increas
potenc
mab
group
start
clonal
variant
isol
donor
patient
enhanc
neutral
abil
structur
two
mab
highli
similar
contain
sequenc
ident
heavi
chain
variabl
vh
domain
sequenc
ident
light
chain
variabl
vl
domain
howev
includ
fourresidu
insert
within
third
heavi
chain
complementar
determin
region
rel
residu
observ
contribut
bind
antibodi
bind
site
diskin
et
al
care
examin
crystal
structur
bound
note
key
interact
residu
phenylalanin
hydrophob
pocket
mimick
either
antibodi
hypothes
mutat
residu
mab
interact
hydrophob
pocket
would
increas
mab
potenc
breadth
figur
seri
mutant
therefor
construct
contain
hydrophob
amino
acid
substitut
residu
gli
nativ
close
proxim
hydrophob
pocket
saw
expect
contain
mutat
show
increas
neutral
potenc
remark
show
substanti
increas
breadth
strain
neutral
compar
parent
higher
neutral
abil
strain
work
provid
eleg
exampl
structur
base
ration
design
use
construct
potent
antivir
antibodi
potenti
use
passiv
immun
treatment
viral
infect
recent
work
tharakaraman
et
al
util
novel
comput
approach
reliant
crystal
structur
inform
increas
potenc
antibodi
dengu
viru
denv
denv
flaviviru
respons
million
human
infect
per
year
rang
sever
acut
febril
ill
fatal
hemorrhag
fever
shock
syndrom
denv
consist
four
serotyp
vari
one
anoth
amino
acid
level
importantli
denv
infect
character
mark
antibodydepend
enhanc
replic
wherebi
higher
level
viral
replic
lethal
observ
denv
survivor
second
infect
denv
serotyp
primari
infect
three
serotyp
phenomenon
previou
vaccin
trial
denv
fail
current
interest
focus
antibodi
inhibit
multipl
serotyp
work
tharakaraman
et
al
comput
redesign
antibodi
direct
denv
viral
envelop
glycoprotein
e
previous
identifi
mice
found
potent
neutral
abil
limit
neutral
potenti
therefor
group
strove
improv
affin
maintain
affin
antibodi
reli
comput
dock
model
recent
structur
singl
chain
variabl
fragment
scfv
complex
e
domain
iii
four
serotyp
report
tharakaraman
et
al
studi
initi
structur
yet
avail
group
first
use
multivari
logist
regress
analysi
mlr
identifi
key
physiochem
featur
defin
natur
antigenantibodi
interfac
allow
accur
predict
correct
antibodyantigen
complex
standard
dock
protocol
reli
sole
energi
minim
function
use
mlr
result
model
bound
e
protein
gener
model
use
design
mutat
predict
increas
antibodi
affin
detriment
affect
contact
one
mutant
contain
five
amino
acid
substitut
found
greatest
increas
affin
toward
compar
redesign
display
enhanc
affin
enhanc
affin
maintain
affin
vitro
neutral
assay
show
neutral
increas
potenc
maintain
potenc
addit
demonstr
potent
antivir
activ
four
denv
strain
mous
model
infect
caus
signific
reduct
viremia
mgkg
mgkg
recent
work
varani
laboratori
also
appli
comput
method
improv
neutral
capabl
antidenv
antibodi
nmr
epitop
map
use
defin
bind
site
broadli
neutral
human
mab
four
denv
serotyp
structur
inform
use
filter
result
comput
dock
analysi
best
dock
model
allow
group
ration
engin
mutant
bound
one
serotyp
therebi
demonstr
abil
increas
antibodi
specif
bound
tightli
eptiop
result
mutant
time
effect
parent
neutral
denv
note
group
use
comput
model
past
explor
antidenv
antibodi
fail
neutral
viral
infect
examin
bind
two
neutral
mab
influenza
ha
protein
exampl
outlin
demonstr
comput
method
appli
studi
antibodyviru
interact
inform
use
develop
effect
antivir
mab
contrast
comput
model
start
antibodi
requir
synthet
antibodi
engin
show
promis
develop
novel
antibodi
viral
target
antibodi
avail
synthet
antibodi
contain
antigenbind
site
construct
entir
ration
design
manmad
divers
key
advantag
compar
tradit
method
synthet
antibodi
engin
reli
previou
human
anim
infectionimmun
therefor
possibl
select
antibodi
tradit
nonimmunogen
target
target
viral
epitop
conform
may
aris
natur
infect
synthet
antibodi
librari
display
surfac
filament
bacteriophag
phage
display
use
select
antibodi
bind
target
ubiquitin
histon
hemoglobin
select
precis
antigen
conform
antibodi
exquisit
specif
obtain
synthet
antibodi
librari
antibodi
distinguish
chicken
quail
lysozym
differ
four
amino
acid
differenti
two
conform
enzym
caspas
addit
advantag
initi
librari
typic
construct
human
scaffold
therefor
result
antibodi
requir
extens
engin
human
prior
therapeut
use
despit
advantag
offer
synthet
antibodi
phage
display
techniqu
recent
appli
discoveri
antibodi
target
viral
epitop
laboratori
use
technolog
target
fusion
intermedi
ebola
viru
ebov
envelop
glycoprotein
gp
ebov
highli
patholog
member
filovirida
famili
virus
caus
sever
hemorrhag
fever
viral
entri
mediat
gp
consist
three
copi
surfac
subunit
transmembran
subunit
bind
cell
surfac
receptor
initi
uptak
viru
endosom
host
cystein
proteas
cleav
gp
remov
cleavag
event
shown
necessari
ebov
entri
cleavag
hypothes
import
viral
entri
two
reason
cleavag
thought
unmask
receptor
bind
site
neimann
pick
endosom
cholesterol
transport
recent
shown
critic
intracellular
receptor
ebov
entri
ii
cleavag
appear
prime
subunit
largescal
conform
chang
ultim
lead
fusion
viral
host
endosom
membran
howev
structur
chang
gp
associ
endosom
proteolyt
cleavag
incomplet
defin
precis
time
cleavag
within
endosom
poorli
understood
addit
unclear
whether
epitop
proteolyt
cleav
gp
avail
viru
neutral
therefor
strove
identifi
novel
mab
capabl
distinguish
uncleav
gp
uncl
proteolyt
cleav
gp
cl
form
gp
howev
limit
sourc
natur
human
ebola
viru
antibodi
sinc
survivor
gener
low
serum
antibodi
titer
mani
respons
domin
antibodi
bind
preferenti
secret
dimer
form
gp
sgp
relev
membran
fusion
identifi
mab
specif
recognit
profil
toward
gp
uncl
gp
cl
use
synthet
antibodi
bind
fragment
fab
librari
base
human
antimaltos
bind
protein
fab
scaffold
librari
librari
f
contain
binomi
tyrosineserin
random
nonstructur
posit
addit
variat
encod
nine
residu
tyrserglyalaphetrphisprov
ratio
amino
acid
distribut
mimic
observ
distribut
found
natur
cdr
segment
screen
librari
f
protein
mimic
gp
uncl
gp
cl
identifi
antibodi
distinct
recognit
profil
fab
cl
bound
preferenti
gp
cl
ec
nm
wherea
fab
uncl
bound
specif
gp
uncl
ec
nm
neutral
assay
gpcontain
pseudotyp
virus
indic
antibodi
inhibit
gp
cl
gp
uncl
mediat
viral
entri
specif
match
recognit
profil
ic
nm
igg
cl
fab
uncl
work
demonstr
epitop
gp
cl
avail
neutral
antibodi
may
lead
develop
new
tool
dissect
intermedi
ebov
entri
importantli
result
demonstr
applic
synthet
antibodi
engin
studi
viral
membran
fusion
pave
way
synthet
antibodi
librari
screen
viral
target
limit
sourc
natur
human
antibodi
ration
comput
combinatori
method
hold
great
promis
applic
protein
engin
principl
viral
vaccin
immunotherapeut
develop
furthermor
number
bnab
character
structur
studi
increas
steadili
recent
year
provid
addit
inform
base
design
much
progress
made
engin
new
viral
immunogen
antibodi
challeng
move
forward
evalu
reagent
appropri
anim
model
expect
futur
work
provid
new
fundament
insight
requir
protect
neutral
virus
vivo
neutral
antibodi
thought
abrog
viral
infect
block
viru
attach
host
cell
inhibit
viral
uncoat
block
conform
chang
viral
envelop
glycoprotein
need
membran
fusion
prematur
trigger
fusion
machineri
induc
format
noninfecti
viral
aggreg
enter
cell
structur
biochem
studi
use
defin
epitop
bnab
linear
discontinu
epitop
residu
involv
antibodyantigen
interact
graft
onto
stabl
scaffold
appropri
conform
origin
antigen
modifi
optim
recognit
properti
follow
confirm
antibodi
bind
engin
immunogen
use
elicit
broadli
neutral
antibodi
respons
anim
model
way
addit
bnab
may
identifi
potenti
use
immunogen
vaccin
develop
may
assess
depict
revers
engin
process
use
two
bnab
recogn
discontinu
epitop
recogn
continu
linear
epitop
structur
core
show
bind
site
yellow
residu
modifi
resurfac
red
residu
modif
chosen
elimin
antigen
region
therebi
focu
immun
respons
molecul
bind
site
modifi
molecul
use
bait
screen
use
broadli
neutral
serum
human
patient
result
identif
potent
bnab
pdb
id
b
schemat
engin
scheme
jardin
et
al
order
engag
germlin
precursor
inset
show
nativ
green
engin
molecul
pink
bind
germlin
antibodi
fab
cyan
germlin
precursor
taken
pdb
id
pdb
id
potenti
steric
clash
glycan
posit
germlin
precursor
predict
glycan
drawn
inset
figur
red
stick
asn
residu
mutat
asp
therebi
remov
clash
diskin
et
al
note
neither
mab
blue
recapitul
key
interact
pink
residu
phe
hydrophob
pocket
green
seri
mutant
construct
contain
hydrophob
amino
acid
substitut
residu
gli
shown
stick
inset
contain
mutat
show
increas
neutral
potenc
breadth
